Browse the evidence

Semaglutide use is associated with a substantial decrease in long-term relative body weight of -12.1% compared to placebo.

Semaglutide can be considered an effective treatment option for weight loss in patients with obesity who do not have diabetes.

33.4% of participants randomized to semaglutide achieved ≥20% weight loss compared to 2.2% with placebo.

A significant proportion of patients may achieve substantial weight loss with semaglutide, making it a viable option for obesity management.

In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg for 32 weeks led to a mean percentage change in body weight from baseline of -10.09%.

Mazdutide may be an effective treatment option for weight loss in adults with obesity or overweight.

In the 6-mg mazdutide group, the mean percentage change in body weight from baseline at week 32 was -12.55%.

Higher doses of mazdutide may lead to greater weight loss in adults with obesity or overweight.

73.9% of participants in the 4-mg mazdutide group achieved a weight reduction of at least 5% at week 32.

A significant proportion of adults with obesity or overweight may benefit from mazdutide treatment.

Tirzepatide (TZP) resulted in a mean body weight loss of 16.7 kg compared to 8.3 kg with placebo (PBO) after 18 weeks (p<0.001).

Tirzepatide may be an effective treatment for weight loss in individuals with obesity.

TZP significantly decreased food intake during lunch and dinner compared to PBO.

TZP may help reduce overall food consumption in individuals with obesity.

Weight management treatments (WMT) increased the probability of achieving 5% or greater weight loss.

Implementing WMT can significantly enhance weight loss outcomes for patients.

Increasing physical activity is associated with the lowest obesity odds compared to stable physical activity-diet.

Practitioners should encourage increased physical activity to reduce obesity risk.

Increasing physical activity with improved diet is associated with the largest reductions in body fat percentage, body mass index, and waist circumference.

Encouraging both increased physical activity and dietary improvements can maximize fat loss.

Time-restricted feeding (TRF) combined with a low-calorie diet resulted in significantly greater reductions in weight, BMI, waist circumference, and body fat mass compared to a low-calorie diet alone after 8 weeks.

Practitioners may consider recommending TRF combined with a low-calorie diet for better weight management in overweight and obese women with food addiction.

94.2% of patients achieved ≥ 5% weight loss after 6 months of tirzepatide treatment.

Practitioners can expect a high rate of significant weight loss among patients using tirzepatide.

HP diets, whether rich or restricted in red meat, are effective for decreasing body fat.

Practitioners can recommend HP diets, including lean beef, for weight loss.

Consuming lean beef as part of a HP diet does not negatively impact body fat loss compared to a diet restricted in red meats.

Lean beef can be included in HP diets without compromising fat loss.

Body fat percentage and fat mass significantly decreased during the 16-week intervention.

Weight loss interventions can lead to significant reductions in body fat and fat mass.

The 5:2 total diet replacement (5:2TDR) resulted in a weight loss of -0.9 kg after 26 weeks, while the once-daily meal-replacement (DMR) group experienced a weight regain of 3.5 kg, leading to a between-group difference of -4.4 kg.

Practitioners may consider recommending 5:2TDR for better weight maintenance outcomes compared to DMR.

Both dietary interventions (5:2TDR and DMR) maintained weight losses greater than 15 kg below baseline at 26, 52, and 78 weeks.

Both interventions can be effective for long-term weight maintenance.

At 5-6 months, the mean weight reduction was 7.9%, with 56% of participants achieving more than 5% weight loss.

Phentermine/topiramate ER can be effective for weight loss in obese patients.

At 12 months, patients who persisted in treatment experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

Long-term adherence to treatment can lead to significant weight loss.

Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.

Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.

82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.

A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.